In a clinical study, Michael Ouk et al. [117] reported that among APOE ε4 non-carriers with AD, ARB use was related to the greater preservation of memory and attention/psychomotor processing speed, particularly compared with ACEIs that do not cross the blood-brain-barrier (RR = 1.200, p = 0.003). Here, APOE is linked to Alzheimer disease.